Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2018

  • ID: 4538980
  • Clinical Trials
  • Region: Global
  • 3085 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • Novartis AG
  • MORE
Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2018

Summary

The clinical trial report, “Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2018" provides an overview of Non-Small Cell Lung Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Small Cell Lung Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The Clinical Trial Reports are generated using the author's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • Novartis AG
  • MORE
  • Report Guidance
  • Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Non-Small Cell Lung Cancer Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Non-Small Cell Lung Cancer
  • Apr 10, 2018: BerGenBio Completes Recruitment Into First Stage of Phase II NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA
  • Apr 10, 2018: Spectrum Pharmaceuticals Announces Update of MD Anderson’s Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients
  • Apr 09, 2018: NICE gives Green Light to New Immunotherapy for most Common form of Lung Cancer
  • Apr 09, 2018: KEYTRUDA (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor Cells
  • Apr 09, 2018: G1 Therapeutics to Present Preclinical Data on G1T38 at the 2018 American Association for Cancer Research (AACR) Annual Meeting
  • Apr 05, 2018: Molecular Partners to present MP0310 pre-clinical data at the AACR Annual Meeting 2018
  • Apr 05, 2018: Molecular Partners to present MP0250 clinical abstract at the AACR Annual Meeting 2018
  • Apr 04, 2018: Loxo Oncology Announces Acceptance of LOXO-292 Oral Presentation at the American Society of Clinical Oncology Annual Meeting
  • Apr 04, 2018: Vaccibody as Announces Informed Consent Signed by First Patient and Enrollment Process Initiated in the Cancer Neoantigen Phase I/IIA Clinical Trial
  • Apr 02, 2018: Lung cancer drug shows promise as targeted therapy for thousands with breast cancer
  • Mar 22, 2018: BerGenBio to present overview of phase II clinical trial portfolio combining bemcentinib with KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe
  • Mar 22, 2018: Oncology Venture Sweden: Scientific Journal Highlights Study Of The Drp Tool In Cisplatin Treatment For Patients With Lung Cancer
  • Mar 19, 2018: Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Squamous Lung Cancer
  • Mar 15, 2018: OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
  • Mar 14, 2018: Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018
  • Mar 14, 2018: First-Line Lung Cancer Data and Other New Research from Merck’s Broad Oncology Program to be Presented at AACR Annual Meeting
  • Mar 14, 2018: TESARO to Present Data on Oncology Product Candidate TSR-042 at AACR 2018 Annual Meeting
  • Mar 14, 2018: Research from Bristol-Myers Squibb’s Innovative Oncology Development Program to Be Presented at AACR 2018 Demonstrates Commitment to Advancing Precision Medicine Research for Patients with Cancer
  • Mar 12, 2018: AstraZeneca Provides Update on MYSTIC Trial Timeline
  • Mar 12, 2018: Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer
  • Feb 28, 2018: Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer
  • Feb 27, 2018: OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
  • Feb 23, 2018: L-DOS47 US Phase I Study Presentation at the IASLC 18th Annual Target Therapies of Lung Cancer Meeting
  • Feb 22, 2018: Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer
  • Feb 15, 2018: Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
  • Feb 14, 2018: Heat Biologics Announces Poster Presentation of Interim Phase 2 Lung Cancer Clinical Data for HS-110 and Nivolumab at the 2018 Keystone Symposia Conference XI: Immunological Memory: Innate, Adaptive and Beyond
  • Feb 13, 2018: Chi-Med Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer
  • Feb 07, 2018: Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
  • Feb 07, 2018: Xcovery Announces Initiation of Phase 2 Clinical Trial for Ensartinib in Melanoma Patients with ALK Alternations
  • Feb 05, 2018: Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer Patients with High Tumor Mutation Burden
  • Jan 31, 2018: Puma Biotechnology Announces Publication of Results from Phase II SUMMIT ‘Basket’ Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancer
  • Jan 30, 2018: Heat Biologics to Host Analyst and Investor Event February 28, 2018 to Present Results from its Phase 2 Lung Cancer Study
  • Jan 23, 2018: Biomarck Announces the Start of a Phase 2 Clinical Trial of BIO-11006 for Non-Small Cell Lung Cancer
  • Jan 16, 2018: First Patient Dosed in a Phase 2 Trial with Transgene TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)
  • Jan 16, 2018: Merck’s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment in Combination with Pemetrexed and Platinum Chemotherapy for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (KEYNOTE-189)
  • Clinical Trial Profile Snapshots
  • Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About
  • Contact
  • Disclaimer
  • Source
List of Tables
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region, 2018*
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries, 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018*
  • Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2018*
  • Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
  • Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
  • Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2018*
  • Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
  • Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase, 2018*
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2018*
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
  • Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
List of Figures
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region (%), 2018*
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018*
  • Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2018*
  • Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
  • Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
  • Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2018*
  • Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
  • Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2018*
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2018*
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
  • Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
  • Methodology 3
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca Plc
  • Eli Lilly and Co
  • Bristol-Myers Squibb Co
  • Pfizer Inc
  • Sarah Cannon Research Institute LLC
  • Merck & Co Inc
  • Novartis AG
  • C. H. Boehringer Sohn AG & Co KG
  • Sanofi
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll